Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24783320 | 0.75 | CRBN (0.54) | CRBNDDB1KDM4EALDH1A1 | |
| SCHEMBL24783470 | 0.67 | CRBN (0.56) | CRBNDDB1 | |
| SCHEMBL26749205 | 0.65 | CA2 (0.55) | CRBNDDB1ALDH1A1 | |
| SCHEMBL10284715 | 0.63 | MAP4K4 (0.43) | MAP4K4KDM4EALDH1A1POLBPDE9A | |
| SCHEMBL22440129 | 0.63 | DDB1 (0.51) | CRBNDDB1ALDH1A1NR3C2 | |
| SCHEMBL26951227 | 0.63 | KDM4E (0.38) | MAP4K4KDM4EALDH1A1POLBPDE9A | |
| SCHEMBL7899620 | 0.63 | MAP4K4 (0.38) | MAP4K4KDM4EALDH1A1POLBPDE9A | |
| SCHEMBL22440147 | 0.63 | HSD11B1 (0.30) | — | |
| SCHEMBL24783460 | 0.62 | CRBN (0.60) | CRBNDDB1 | |
| SCHEMBL24784167 | 0.62 | DDB1 (0.45) | CRBNDDB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220251061-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| EP-3710002-A2 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111372585-A | Degradants and degreddeterminants for target protein degradation | C4医药公司 | 2020-07-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | CRBN 25/4885MAP4K4 4024/4885DDB1 1105/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | CRBN 37/4885MAP4K4 3766/4885DDB1 292/4885 |
| US-20220251061-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | CRBN 37/4885MAP4K4 3766/4885DDB1 292/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | CRBN 37/4885MAP4K4 3766/4885DDB1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.